Prolonged delivery of HIV-1 vaccine nanoparticles from hydrogels.
Antigen PEGylation
Co-delivery
Env
HIV vaccine
PEG hydrogel
Silica nanoparticles
Sustained release
Journal
International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127
Informations de publication
Date de publication:
19 Apr 2024
19 Apr 2024
Historique:
received:
13
02
2024
revised:
14
04
2024
accepted:
15
04
2024
medline:
22
4
2024
pubmed:
22
4
2024
entrez:
21
4
2024
Statut:
aheadofprint
Résumé
Immunization is a straightforward concept but remains for some pathogens like HIV-1 a challenge. Thus, new approaches towards increasing the efficacy of vaccines are required to turn the tide. There is increasing evidence that antigen exposure over several days to weeks induces a much stronger and more sustained immune response compared to traditional bolus injection, which usually leads to antigen elimination from the body within a couple of days. Therefore, we developed a poly(ethylene) glycol (PEG) hydrogel platform to investigate the principal feasibility of a sustained release of antigens to mimic natural infection kinetics. Eight-and four-armed PEG macromonomers of different MWs (10, 20, and 40 kDa) were end-group functionalized to allow for hydrogel formation via covalent cross-linking. An HIV-1 envelope (Env) antigen in its trimeric (Env
Identifiants
pubmed: 38643811
pii: S0378-5173(24)00365-X
doi: 10.1016/j.ijpharm.2024.124131
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
124131Informations de copyright
Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.